AMT
Investors Home

Amsterdam Molecular Therapeutics (Euronext: AMT) is a leading gene therapy company, with a unique platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy to become a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform.More » More »
Recent News
DateTitle
05/06/10Professor Sander van Deventer appointed to Supervisory Board of AMT
03/10/10Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
02/24/10Amsterdam Molecular Therapeutics Reports Full Year Results 2009
01/25/10EMA starts formal review of Glybera® dossier
More »
Upcoming Events
There are currently no events scheduled.
More »
 
Latest Results
Amsterdam Molecular Therapeutics Reports Full Year Results 2009
Featured Report
Download Documentation Annual Report 2009